

Figure S1: Morphological aspects of MDA-MB 231 cells. (A) 24 h; (B) 72 h; (1. Untreated; 2–5 treated with 0.5 mM, 1 mM, 2 mM, 4 mM);

Figure S2: Akt1 expression. (A) MCF-10a; (B) MDA-MB 231; (Control–untreated, sevoflurane–treated 2mM);

Figure S3: Akt2 expression. (A) MCF-10a; (B) MDA-MB 231; (Control–untreated, sevoflurane–treated 2mM);

Figure S4: Akt3 expression. (A) MCF-10A; (B) MDA-MB 231; (Control–untreated, sevoflurane–treated 2 mM);

Figure S5A: Vimentin expression. (A) MCF-10A; (Control–untreated, sevoflurane–treated 2 mM);

Figure S5B: Vimentin expression. (B) MDA-MB 231; (Control–untreated, sevoflurane–treated 2 mM).